RESUMEN
LIM domains are required for both inhibitory effects on LIM homeodomain transcription factors and synergistic transcriptional activation events. The inhibitory actions of the LIM domain can often be overcome by the LIM co-regulator known as CLIM2, LDB1 and NLI (referred to hereafter as CLIM2; refs 2-4). The association of the CLIM cofactors with LIM domains does not, however, improve the DNA-binding ability of LIM homeodomain proteins, suggesting the action of a LIM-associated inhibitor factor. Here we present evidence that LIM domains are capable of binding a novel RING-H2 zinc-finger protein, Rlim (for RING finger LIM domain-binding protein), which acts as a negative co-regulator via the recruitment of the Sin3A/histone deacetylase corepressor complex. A corepressor function of RLIM is also suggested by in vivo studies of chick wing development. Overexpression of the gene Rnf12, encoding Rlim, results in phenotypes similar to those observed after inhibition of the LIM homeodomain factor LHX2, which is required for the formation of distal structures along the proximodistal axis, or by overexpression of dominant-negative CLIM1. We conclude that Rlim is a novel corepressor that recruits histone deacetylase-containing complexes to the LIM domain.
Asunto(s)
Histona Desacetilasas/metabolismo , Proteínas de Homeodominio/antagonistas & inhibidores , Proteínas Represoras/fisiología , Factores de Transcripción/antagonistas & inhibidores , Secuencia de Aminoácidos , Animales , Células COS , Embrión de Pollo , Extremidades/anatomía & histología , Extremidades/embriología , Regulación del Desarrollo de la Expresión Génica , Ratones , Datos de Secuencia Molecular , Proteínas Represoras/análisis , Homología de Secuencia de Aminoácido , Factores de Tiempo , Distribución Tisular , Transfección , Ubiquitina-Proteína LigasasRESUMEN
Retinoic acid, steroid and thyroid hormones regulate complex programs of gene expression by binding to intracellular receptors that are members of the nuclear receptor superfamily of ligand-dependent transcription factors. Recent studies have led to the identification and cloning of genes encoding coactivator molecules that appear to play important roles in mediating ligand-dependent transcription by members of this family. The identification of these coactivator molecules suggests a point of entry into the general transcriptional machinery that is common to several other classes of regulated transcription factors.
Asunto(s)
Receptores Citoplasmáticos y Nucleares/metabolismo , Transactivadores , Factores de Transcripción/metabolismo , Regulación Alostérica , Animales , Proteína de Unión a CREB , Histona Acetiltransferasas , Humanos , Proteínas Nucleares/metabolismo , Coactivador 1 de Receptor Nuclear , Coactivador 2 del Receptor Nuclear , Transducción de SeñalRESUMEN
The HIV-1 Rev protein facilitates the nuclear export of mRNA containing the Rev response element (RRE) through binding to the export receptor CRM-1. Here we show that a cellular nuclear protein, Sam68 (Src-associated protein in mitosis), specifically interacts with RRE and can partially substitute for as well as synergize with Rev in RRE-mediated gene expression and virus replication. Differential sensitivity to leptomycin B, an inhibitor of CRM-1, indicates that the export pathways mediated by Rev and Sam68 are distinct. C-terminally deleted mutants of Sam68 inhibited the transactivation of RRE-mediated expression by both wild-type Sam68 and Rev. They were retained in the cytoplasm and impeded the nuclear localization of Rev in co-expressed cells. These mutants also inhibited wild-type HIV-1 replication to the same extent as the RevM10 mutant, and may be useful as anti-viral agents in the treatment of AIDS.
Asunto(s)
Productos del Gen rev , VIH-1/fisiología , Carioferinas , Proteínas de Unión al ARN/genética , Proteínas de Unión al ARN/metabolismo , Receptores Citoplasmáticos y Nucleares , Replicación Viral/genética , Proteínas Adaptadoras Transductoras de Señales , Anticuerpos/metabolismo , Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/metabolismo , Células Cultivadas/virología , Cloranfenicol O-Acetiltransferasa/genética , Citoplasma/metabolismo , Proteínas de Unión al ADN , Inhibidores Enzimáticos/farmacología , Ácidos Grasos Insaturados/farmacología , Regulación Viral de la Expresión Génica , Genes Dominantes , Genes Reporteros , Células HeLa/virología , Humanos , Cinetina , Mutación , Purinas/farmacología , Proteínas de Unión al ARN/antagonistas & inhibidores , Elementos de Respuesta , Productos del Gen rev del Virus de la Inmunodeficiencia Humana , Proteína Exportina 1RESUMEN
Human fibroblasts have a limited replicative life span when maintained in culture after which they become unresponsive to treatment with mitogens, a phenomenon most commonly called senescence. Experiments indicating that serum does not induce expression of the c-fos proto-oncogene in senescent fibroblasts raised the issue of a potential central role for c-fos in the phenotype of sustained growth arrest. This was directly tested by microinjection of oncogenic c-Ha-ras protein into senescent fibroblasts. While ras injection was found to induce marked nuclear c-fos expression and functional AP-1 transcription activity, this did not lead to DNA synthesis. These results suggest that the senescence phenotype cannot be solely attributed to the absence of c-fos expression and that the proliferative block in these cells is either independent of AP-1 transcriptional activity, downstream of it, or involves multiple molecular mechanisms.
Asunto(s)
Senescencia Celular/fisiología , Fibroblastos/fisiología , Proteínas Proto-Oncogénicas c-fos/biosíntesis , Proteínas Proto-Oncogénicas p21(ras)/farmacología , Factores de Transcripción/biosíntesis , División Celular/efectos de los fármacos , División Celular/fisiología , Senescencia Celular/efectos de los fármacos , Fibroblastos/citología , Fibroblastos/efectos de los fármacos , Expresión Génica , Humanos , Microinyecciones , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas c-fos/efectos de los fármacos , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/efectos de los fármacos , Factores de Transcripción/efectos de los fármacos , beta-Galactosidasa/biosíntesis , beta-Galactosidasa/efectos de los fármacosRESUMEN
Reciprocal gene activation and restriction during cell type differentiation from a common lineage is a hallmark of mammalian organogenesis. A key question, then, is whether a critical transcriptional activator of cell type-specific gene targets can also restrict expression of the same genes in other cell types. Here, we show that whereas the pituitary-specific POU domain factor Pit-1 activates growth hormone gene expression in one cell type, the somatotrope, it restricts its expression from a second cell type, the lactotrope. This distinction depends on a two-base pair spacing in accommodation of the bipartite POU domains on a conserved growth hormone promoter site. The allosteric effect on Pit-1, in combination with other DNA binding factors, results in the recruitment of a corepressor complex, including nuclear receptor corepressor N-CoR, which, unexpectedly, is required for active long-term repression of the growth hormone gene in lactotropes.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , ADN/metabolismo , Regulación de la Expresión Génica , Hormona del Crecimiento/genética , Hipófisis/metabolismo , Prolactina/genética , Proteínas Represoras/metabolismo , Factores de Transcripción/metabolismo , Regulación Alostérica , Animales , Secuencia de Bases , Sitios de Unión , Línea Celular , Secuencia Conservada , Cristalización , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/genética , Femenino , Genes Reporteros , Masculino , Ratones , Ratones Transgénicos , Modelos Moleculares , Datos de Secuencia Molecular , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Co-Represor 1 de Receptor Nuclear , Hipófisis/citología , Regiones Promotoras Genéticas , Conformación Proteica , Estructura Terciaria de Proteína , Ratas , Proteínas Represoras/química , Proteínas Represoras/genética , Factor de Transcripción Pit-1 , Factores de Transcripción/química , Factores de Transcripción/genética , Activación TranscripcionalRESUMEN
Different classes of mammalian transcription factors-nuclear receptors, cyclic adenosine 3',5'-monophosphate-regulated enhancer binding protein (CREB), and signal transducer and activator of transcription-1 (STAT-1)-functionally require distinct components of the coactivator complex, including CREB-binding protein (CBP/p300), nuclear receptor coactivators (NCoAs), and p300/CBP-associated factor (p/CAF), based on their platform or assembly properties. Retinoic acid receptor, CREB, and STAT-1 also require different histone acetyltransferase (HAT) activities to activate transcription. Thus, transcription factor-specific differences in configuration and content of the coactivator complex dictate requirements for specific acetyltransferase activities, providing an explanation, at least in part, for the presence of multiple HAT components of the complex.
Asunto(s)
Acetiltransferasas/metabolismo , Proteínas de Ciclo Celular/metabolismo , Proteínas Nucleares/metabolismo , Proteínas de Saccharomyces cerevisiae , Factores de Transcripción/metabolismo , Transcripción Genética , Acetiltransferasas/genética , Proteína de Unión a CREB , Proteínas de Ciclo Celular/genética , AMP Cíclico/metabolismo , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Proteínas de Unión al ADN/metabolismo , Regulación de la Expresión Génica , Células HeLa , Histona Acetiltransferasas , Humanos , Ligandos , Mutación , Co-Represor 1 de Receptor Nuclear , Coactivador 1 de Receptor Nuclear , Coactivador 3 de Receptor Nuclear , Regiones Promotoras Genéticas , Receptores de Ácido Retinoico/metabolismo , Proteínas Represoras/metabolismo , Factor de Transcripción STAT1 , Transactivadores/metabolismo , Factores de Transcripción/genética , Activación Transcripcional , Factores de Transcripción p300-CBPRESUMEN
The transcriptional repressor, REST, helps restrict neuronal traits to neurons by blocking their expression in nonneuronal cells. To examine the repercussions of REST expression in neurons, we generated a neuronal cell line that expresses REST conditionally. REST expression inhibited differentiation by nerve growth factor, suppressing both sodium current and neurite growth. A novel corepressor complex, CoREST/HDAC2, was shown to be required for REST repression. In the presence of REST, the CoREST/HDAC2 complex occupied the native Nav1.2 sodium channel gene in chromatin. In neuronal cells that lack REST and express sodium channels, the corepressor complex was not present on the gene. Collectively, these studies define a novel HDAC complex that is recruited by the C-terminal repressor domain of REST to actively repress genes essential to the neuronal phenotype.
Asunto(s)
Corteza Cerebral/fisiología , Neuronas/fisiología , Proteínas Represoras/metabolismo , Factores de Transcripción/metabolismo , Animales , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Células COS , Diferenciación Celular/efectos de los fármacos , Línea Celular , Células Cultivadas , Chlorocebus aethiops , Cromatina/fisiología , Proteínas de Unión al ADN/metabolismo , Embrión de Mamíferos , Histona Desacetilasa 2 , Histona Desacetilasas/genética , Histona Desacetilasas/metabolismo , Humanos , Ratones , Ratones Endogámicos C57BL , Canal de Sodio Activado por Voltaje NAV1.2 , Factor de Crecimiento Nervioso/farmacología , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/fisiología , Neuronas/citología , Neuronas/efectos de los fármacos , Células PC12 , Ratas , Proteínas Recombinantes de Fusión/metabolismo , Proteínas Recombinantes/metabolismo , Proteínas Represoras/genética , Serina Endopeptidasas/genética , Serina Endopeptidasas/metabolismo , Canales de Sodio/genética , Canales de Sodio/fisiología , Factores de Transcripción/genética , Transfección , Dedos de ZincRESUMEN
We have recently identified the Raf kinase inhibitor protein (RKIP) as a physiological endogenous inhibitor of the Raf-1/MEK/extracellular signal-regulated kinase (ERK) pathway. RKIP interfered with MEK phosphorylation and activation by Raf-1, resulting in the suppression of both Raf-1-induced transformation and AP-1-dependent transcription. Here we report the molecular mechanism of RKIP's inhibitory function. RKIP can form ternary complexes with Raf-1, MEK, and ERK. However, whereas MEK and ERK can simultaneously associate with RKIP, Raf-1 binding to RKIP and that of MEK are mutually exclusive. RKIP is able to dissociate a Raf-1-MEK complex and behaves as a competitive inhibitor of MEK phosphorylation. Mapping of the binding domains showed that MEK and Raf-1 bind to overlapping sites in RKIP, whereas MEK and RKIP associate with different domains in Raf-1, and Raf-1 and RKIP bind to different sites in MEK. Both the Raf-1 and the MEK binding sites in RKIP need to be destroyed in order to relieve RKIP-mediated suppression of the Raf-1/MEK/ERK pathway, indicating that binding of either Raf-1 or MEK is sufficient for inhibition. The properties of RKIP reveal the specific sequestration of interacting components as a novel motif in the cell's repertoire for the regulation of signaling pathways.
Asunto(s)
Proteína de Unión a Andrógenos , Proteínas Portadoras/metabolismo , Proteínas Proto-Oncogénicas c-raf/metabolismo , Transducción de Señal , Alelos , Proteínas Portadoras/genética , Genes Reporteros , Glutatión Transferasa/metabolismo , Modelos Biológicos , Proteínas de Transferencia de Fosfolípidos , Plásmidos , Unión Proteica , Proteínas Serina-Treonina Quinasas/química , Proteínas Serina-Treonina Quinasas/metabolismo , Estructura Terciaria de Proteína , Proteínas Proto-Oncogénicas c-raf/química , Proteínas Proto-Oncogénicas c-raf/genética , Proteínas Recombinantes de Fusión/metabolismo , Técnicas del Sistema de Dos HíbridosRESUMEN
Cellular growth control requires the coordination and integration of multiple signaling pathways which are likely to be activated concomitantly. Mitogenic signaling initiated by thyrotropin (TSH) in thyroid cells seems to require two distinct signaling pathways, a cyclic AMP (cAMP)-dependent signaling pathway and a Ras-dependent pathway. This is a paradox, since activated cAMP-dependent protein kinase disrupts Ras-dependent signaling induced by growth factors such as epidermal growth factor and platelet-derived growth factor. This inhibition may occur by preventing Raf-1 protein kinase from binding to Ras, an event thought to be necessary for the activation of Raf-1 and the subsequent activation of the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinases (MEKs) and MAP kinase (MAPK)/ERKs. Here we report that serum-stimulated hyperphosphorylation of Raf-1 was inhibited by TSH treatment of Wistar rat thyroid cells, indicating that in this cell line, as in other cell types, increases in intracellular cAMP levels inhibit activation of downstream kinases targeted by Ras. Ras-stimulated expression of genes containing AP-1 promoter elements was similarly inhibited by TSH. On the other hand, stimulation of thyroid cells with TSH resulted in stimulation of DNA synthesis which was Ras dependent but both Raf-1 and MEK independent. We also show that Ras-stimulated DNA synthesis required the use of this kinase cascade in untreated quiescent cells but not in TSH-treated cells. These data suggest that in TSH-treated thyroid cells, Ras might be able to signal through effectors other than the well-studied cytoplasmic kinase cascade.
Asunto(s)
Proteínas Quinasas/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Receptor de Insulina/metabolismo , Transducción de Señal/fisiología , Tirotropina/farmacología , Proteínas ras/metabolismo , Animales , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , División Celular/efectos de los fármacos , Línea Celular , AMP Cíclico/fisiología , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Citoplasma/enzimología , ADN/biosíntesis , Activación Enzimática , Expresión Génica , Inmunoglobulina G/farmacología , Fosforilación , Proteínas Proto-Oncogénicas c-raf , Ratas , Ratas Wistar , Receptor de Insulina/biosíntesis , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/metabolismo , Transducción de Señal/efectos de los fármacos , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/metabolismo , Transfección , Proteínas ras/biosíntesisRESUMEN
We have investigated the functional role of the SH2 domain of the 85-kDa subunit (p85) of the phosphatidylinositol 3-kinase in the insulin signal transduction pathway. Microinjection of a bacterial fusion protein containing the N-terminal SH2 domain of p85 inhibited insulin- and other growth factor-induced DNA synthesis by 90% and c-fos protein expression by 80% in insulin-responsive rat fibroblasts. The specificity of the fusion protein was examined by in vitro precipitation experiments, which showed that the SH2 domain of p85 can independently associate with both insulin receptor substrate 1 and the insulin receptor itself in the absence of detectable binding to other phosphoproteins. The microinjection results were confirmed through the use of an affinity-purified antibody directed against p85, which gave the same phenotype. Additional studies were carried out in another cell line expressing mutant insulin receptors which lack the cytoplasmic tyrosine residues with which p85 interacts. Microinjection of the SH2 domain fusion protein also inhibited insulin signaling in these cells, suggesting that association of p85 with insulin receptor substrate 1 is a key element in insulin-mediated cell cycle progression. In addition, coinjection of purified p21ras protein with the p85 fusion protein or the antibody restored DNA synthesis, suggesting that ras function is either downstream or independent of p85 SH2 domain interaction.
Asunto(s)
ADN/biosíntesis , Genes fos/efectos de los fármacos , Insulina/farmacología , Fosfotransferasas (Aceptor de Grupo Alcohol)/farmacología , Animales , Anticuerpos/administración & dosificación , Línea Celular , Humanos , Proteínas Sustrato del Receptor de Insulina , Microinyecciones , Peso Molecular , Fosfatidilinositol 3-Quinasas , Fosfoproteínas/metabolismo , Fosfotransferasas (Aceptor de Grupo Alcohol)/administración & dosificación , Fosfotransferasas (Aceptor de Grupo Alcohol)/química , Conformación Proteica , Proteínas Proto-Oncogénicas c-fos/biosíntesis , Proteínas Proto-Oncogénicas p21(ras)/administración & dosificación , Ratas , Receptor de Insulina/metabolismo , Proteínas Recombinantes de Fusión/administración & dosificación , Transducción de Señal/efectos de los fármacosRESUMEN
The Raf kinase inhibitor protein (RKIP) acts as a negative regulator of the mitogen-activated protein (MAP) kinase (MAPK) cascade initiated by Raf-1. RKIP inhibits the phosphorylation of MAP/extracellular signal-regulated kinase 1 (MEK1) by Raf-1 by disrupting the interaction between these two kinases. We show here that RKIP also antagonizes the signal transduction pathways that mediate the activation of the transcription factor nuclear factor kappa B (NF-kappaB) in response to stimulation with tumor necrosis factor alpha (TNF-alpha) or interleukin 1 beta. Modulation of RKIP expression levels affected NF-kappaB signaling independent of the MAPK pathway. Genetic epistasis analysis involving the ectopic expression of kinases acting in the NF-kappaB pathway indicated that RKIP acts upstream of the kinase complex that mediates the phosphorylation and inactivation of the inhibitor of NF-kappaB (IkappaB). In vitro kinase assays showed that RKIP antagonizes the activation of the IkappaB kinase (IKK) activity elicited by TNF-alpha. RKIP physically interacted with four kinases of the NF-kappaB activation pathway, NF-kappaB-inducing kinase, transforming growth factor beta-activated kinase 1, IKKalpha, and IKKbeta. This mode of action bears striking similarities to the interactions of RKIP with Raf-1 and MEK1 in the MAPK pathway. Emerging data from diverse organisms suggest that RKIP and RKIP-related proteins represent a new and evolutionarily highly conserved family of protein kinase regulators. Since the MAPK and NF-kappaB pathways have physiologically distinct roles, the function of RKIP may be, in part, to coordinate the regulation of these pathways.
Asunto(s)
Proteína de Unión a Andrógenos , Proteínas Portadoras/metabolismo , Proteínas Portadoras/fisiología , Quinasas Quinasa Quinasa PAM/metabolismo , FN-kappa B/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-raf/metabolismo , Animales , Células COS , Línea Celular , Activación Enzimática , Evolución Molecular , Genes Reporteros , Humanos , Interleucina-1/metabolismo , Cinética , Proteínas de Unión a Fosfatidiletanolamina , Proteínas de Transferencia de Fosfolípidos , Fosforilación , Plásmidos/metabolismo , Pruebas de Precipitina , Prostateína , Unión Proteica , Estructura Terciaria de Proteína , Ratas , Secretoglobinas , Transducción de Señal , Transfección , Factor de Necrosis Tumoral alfa/metabolismo , Uteroglobina , Quinasa de Factor Nuclear kappa BRESUMEN
Nuclear factor-kappaB (NF-kappaB) plays a role in the transcriptional regulation of genes involved in inflammation and cell survival. In this report we demonstrate that NF-kappaB recruits a coactivator complex that has striking similarities to that recruited by nuclear receptors. Inactivation of either cyclic AMP response element binding protein (CREB)-binding protein (CBP), members of the p160 family of coactivators, or the CBP-associated factor (p/CAF) by nuclear antibody microinjection prevents NF-kappaB-dependent transactivation. Like nuclear receptor-dependent gene expression, NF-kappaB-dependent gene expression requires specific LXXLL motifs in one of the p160 family members, and enhancement of NF-kappaB activity requires the histone acetyltransferase (HAT) activity of p/CAF but not that of CBP. This coactivator complex is differentially recruited by members of the Rel family. The p50 homodimer fails to recruit coactivators, although the p50-p65 heterodimeric form of the transcription factor assembles the integrator complex. These findings provide new mechanistic insights into how this family of dimeric transcription factors has a differential effect on gene expression.
Asunto(s)
FN-kappa B/metabolismo , Proteínas de Saccharomyces cerevisiae , Activación Transcripcional , Acetiltransferasas/genética , Acetiltransferasas/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Células COS , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/genética , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Histona Acetiltransferasas , FN-kappa B/genética , Coactivador 1 de Receptor Nuclear , Receptores Citoplasmáticos y Nucleares/genética , Receptores Citoplasmáticos y Nucleares/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Factores de Transcripción p300-CBPRESUMEN
Both p21ras and phosphatidylinositol 3-kinase (PI 3-k) are critical elements in signaling pathways mediating insulin/IGF-I induced cell cycle progression. For example, microinjection of antibodies, peptides, or recombinant proteins which block the interaction of the SH2 domains of the PI 3-k p85alpha subunit with tyrosine phosphorylated intracellular targets blocks insulin mediated DNA synthesis. We report here that this inhibitory phenotype is observed whether the injections are made into quiescent cells (the standard approach), or at any time point during G1 phase subsequent to stimulation. This observation is not true, however, for the major substrate of the insulin/IGF-I receptor (IRS-1) despite the well known interaction of p85 with IRS-1. Antibodies to IRS-1 are inhibitory only when injected during the first 15 min of G1 phase, as are antibodies to another major IRS-1 binding protein, the tyrosine phosphatase SHP2. We also have microinjected reagents which target proteins involved in the formation of rasGTP and which mediate some of the downstream effects of ras activation. Reagents which target the formation of rasGTP (Shc and dominant negative ras protein) inhibit DNA synthesis only at points early in G1, as do reagents which target components of the MAP kinase pathway. Injection of antibodies to p21ras itself, or a recombinant Raf-1 protein domain which binds to the effector region of ras in a GTP-dependent manner, results in the inhibition of cell cycle progression throughout G1 phase. The results point to a continuous requirement for both PI 3-k and ras activity until cellular commitment to DNA synthesis, although some of the molecules which are both upstream and downstream of these activities are only required transiently. Our results are also consistent with a Raf-1 independent ras activity late in G1, as well as IRS-1 independent effects of PI 3-kinase.
Asunto(s)
Ciclo Celular/fisiología , Factor I del Crecimiento Similar a la Insulina/fisiología , Insulina/fisiología , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas p21(ras)/metabolismo , Receptor IGF Tipo 1/fisiología , Receptor de Insulina/fisiología , Transducción de Señal/fisiología , Células 3T3 , Animales , Anticuerpos/farmacología , Línea Celular , Fase G1 , Insulina/farmacología , Proteínas Sustrato del Receptor de Insulina , Factor I del Crecimiento Similar a la Insulina/farmacología , Péptidos y Proteínas de Señalización Intracelular , Ratones , Fosfoproteínas/fisiología , Proteína Tirosina Fosfatasa no Receptora Tipo 1 , Proteína Tirosina Fosfatasa no Receptora Tipo 11 , Proteína Tirosina Fosfatasa no Receptora Tipo 6 , Proteínas Tirosina Fosfatasas/metabolismo , Ratas , Receptor de Insulina/genética , Proteínas Recombinantes/metabolismo , TransfecciónRESUMEN
Raf-1 is a serine/threonine specific kinase that integrates signaling by a large number of mitogens to elicit a transcriptional response in the nucleus. Activated Raf-1 phosphorylates and activates MAPK/ERK kinase Mek), thus initiating the Mek--> MAP kinase cascade, which ultimately results in the phosphorylation and activation of transcription factors by MAP kinase. Here we have characterized the mechanism by which monoclonal antibody URP26K, which binds to an epitope in the Raf-1 kinase domain, inhibits intracellular signal transduction. This antibody preferentially immunoprecipitated the underphosphorylated, non-activated form of Raf-1 from quiescent cells. Baculovirus-expressed Raf-1 immunoprecipitated with URP26K was largely refractory to phosphorylation and activation mediated by protein kinase C (PKC)alpha or the tyrosine kinase Lck. In addition, URP26K reduced the binding of Raf-1 to its substrate Mek in vitro, but did not disturb the association of Raf-1 with Ras. Microinjection of URP26K into Rat-1 cells blocked DNA synthesis initiated by serum, insulin and various purified growth factors, but it did not block DNA synthesis initiated by v-ras. Microinjected URP26K also impaired the expression of stably transfected beta-galactosidase reporter genes regulated by minimal promoter elements. These results demonstrate, (i) that the URP26K monoclonal antibody inhibits Raf-1 by preventing activating Raf-1 phosphorylation and/or association with its substrate Mek, (ii) that inhibition of Raf-1 by URP26K does not interfere with Ras-induced DNA synthesis. In contrast to dominant negative Raf-1 mutants, which also block Ras signaling by binding to the Ras effector domain, antibody mediated Raf-1 inhibition thus reveals a branchpoint of mitogenic signaling at the level of Ras.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Quinasa 1 de Quinasa de Quinasa MAP , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas/antagonistas & inhibidores , Transducción de Señal/fisiología , Células 3T3/efectos de los fármacos , Células 3T3/metabolismo , Células 3T3/fisiología , Animales , Anticuerpos Monoclonales/metabolismo , Secuencia Conservada , ADN/biosíntesis , Proteínas de Unión al ADN/metabolismo , Activación Enzimática/efectos de los fármacos , Epítopos/metabolismo , Sustancias de Crecimiento/farmacología , Ratones , Microinyecciones , Fosforilación , Proteínas Serina-Treonina Quinasas/fisiología , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas/fisiología , Proteínas Proto-Oncogénicas c-raf , Transducción de Señal/efectos de los fármacos , Proteínas ras/metabolismo , Proteínas ras/fisiologíaRESUMEN
Rat-1 fibroblasts overexpressing the human insulin receptor undergo rapid actin rearrangement in response to insulin. Breakdown of stress fibers present in quiescent cells is followed by transient membrane ruffling and a return of stress fibers. We investigated the signaling pathways that mediate this insulin-stimulated reorganization of the actin cytoskeleton, which was visualized with rhodamine-phalloidin. Treatment of cells with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor wortmannin prevented insulin action at the preliminary step of stress fiber breakdown. Cellular microinjection of a polyclonal antibody directed against the p85 subunit of PI3-kinase as well as a purified recombinant p85-SH2 domain protein also inhibited actin reorganization. Transient expression of a constitutively active form of PI3-kinase (p110*) was sufficient to cause both stress fiber breakdown and membrane ruffling in the absence of insulin. Microinjection of a polyclonal anti-Shc antibody or dominant negative N17-Ras protein did not affect actin dynamics, and although constitutively active V12-Ras caused modest cytoskeletal reorganization, this effect was blocked by pretreatment with wortmannin. In summary, activation of PI3-kinase is necessary and sufficient to stimulate actin rearrangement, indicating that PI3-kinase may initiate the only signaling cascade required for insulin to induce cytoskeletal restructuring.
Asunto(s)
Citoesqueleto/fisiología , Insulina/farmacología , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Receptor de Insulina/fisiología , Actinas/efectos de los fármacos , Actinas/ultraestructura , Androstadienos/farmacología , Animales , División Celular/efectos de los fármacos , Línea Celular , Citoesqueleto/efectos de los fármacos , Citoesqueleto/ultraestructura , Inhibidores Enzimáticos/farmacología , Factor de Crecimiento Epidérmico/farmacología , Fibroblastos , Humanos , Cinética , Fosfatidilinositol 3-Quinasas , Fosfoproteínas/metabolismo , Fosfotirosina/análisis , Ratas , Receptor de Insulina/biosíntesis , Proteínas Recombinantes/biosíntesis , Estrés Mecánico , Transfección , WortmaninaRESUMEN
Insulin's stimulation of glucose transport involves the translocation of vesicles containing the glucose transporter GLUT4 to the plasma membrane. Small GTP-binding proteins have been implicated in the regulation of vesicular traffic. We studied the effects of microinjection of wild-type Rab4 glutathione S-transferase fusion protein (WT Rab4), a GTP-binding defective mutant (Rab4 N121I), a guanosine triphosphatase-defective mutant (Rab4 Q67L), and a Rab4 antibody on insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Microinjection of Rab4 N121I and Rab4 antibodies had no effect on basal GLUT4 staining, but inhibited insulin-induced GLUT4 translocation by 50% compared with that in control IgG-injected cells. WT Rab4 and Rab4 Q67L microinjection had no effect on either basal or insulin-induced GLUT4 translocation. Premixing and coinjection of the Rab4 antibody with WT Rab4 almost completely abolished its inhibitory effect on insulin-induced GLUT4 translocation. In contrast, microinjection of an antibody directed against the highly conserved region of Rab3 proteins had no effect on insulin-induced GLUT4. These results point to a direct role of Rab4 in insulin-induced GLUT4 translocation, and that this effect is dependent on nucleotide binding to the protein. We also studied the effect of microinjection of the same proteins on insulin-induced actin filament rearrangement (membrane ruffling) in the same cell line. Microinjection of Rab4 N121I and Rab4 antibodies inhibited insulin-induced membrane ruffling by 40%, whereas WT Rab4 or a Rab3 antibody injection had no effect on cytoskeletal rearrangement. In summary, 1) Rab4 is a necessary component of the insulin/GLUT4 translocation signaling pathway; 2) the function of Rab4 in this pathway requires GTP binding; 3) Rab4 also participates in the process of insulin-induced membrane ruffling; and 4) Rab3 proteins do not seem to be involved in these processes.
Asunto(s)
Actinas/fisiología , Adipocitos/fisiología , Proteínas de Unión al GTP/fisiología , Insulina/farmacología , Proteínas de Transporte de Monosacáridos/metabolismo , Proteínas Musculares , Células 3T3 , Adipocitos/metabolismo , Animales , Anticuerpos/inmunología , Anticuerpos/farmacología , Transporte Biológico/efectos de los fármacos , Transporte Biológico/fisiología , Western Blotting , GTP Fosfohidrolasas/genética , GTP Fosfohidrolasas/farmacología , Proteínas de Unión al GTP/genética , Proteínas de Unión al GTP/inmunología , Transportador de Glucosa de Tipo 4 , Glutatión Transferasa/farmacología , Ratones , Microinyecciones , Mutación , Proteínas de Unión al GTP rab3 , Proteínas de Unión al GTP rab4RESUMEN
To delineate the signaling pathway leading to glucose transport protein (GLUT4) translocation, we examined the effect of microinjection of the nonhydrolyzable GTP analog, guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS), into 3T3-L1 adipocytes. Thirty minutes after the injection of 5 mM GTPgammaS, 40% of injected cells displayed surface GLUT4 staining indicative of GLUT4 translocation compared with 55% for insulin-treated cells and 10% in control IgG-injected cells. Treatment of the cells with the phosphatidylinositol 3-kinase inhibitor wortmannin or coinjection of GST-p85 SH2 fusion protein had no effect on GTPgammaS-mediated GLUT4 translocation. On the other hand, coinjection of antiphosphotyrosine antibodies (PY20) blocked GTPgammaS-induced GLUT4 translocation by 65%. Furthermore, microinjection of GTPgammaS led to the appearance of tyrosine-phosphorylated proteins around the periphery of the plasma membrane, as observed by immunostaining with PY20. Treatment of the cells with insulin caused a similar phosphotyrosine-staining pattern. Electroporation of GTPgammaS stimulated 2-deoxy-D-glucose transport to 70% of the extent of insulin stimulation. In addition, immunoblotting with phosphotyrosine antibodies after electroporation of GTPgammaS revealed increased tyrosine phosphorylation of several proteins, including 70- to 80-kDa and 120- to 130-kDa species. These results suggest that GTPgammaS acts upon a signaling pathway either downstream of or parallel to activation of phosphatidylinositol 3-kinase and that this pathway involves tyrosine-phosphorylated protein(s).
Asunto(s)
Guanosina 5'-O-(3-Tiotrifosfato)/farmacología , Proteínas de Transporte de Monosacáridos/metabolismo , Proteínas Musculares , Tirosina/metabolismo , Células 3T3 , Adipocitos/metabolismo , Animales , Transporte Biológico/efectos de los fármacos , Electroporación , Transportador de Glucosa de Tipo 4 , Ratones , Microinyecciones , Peso Molecular , Fosfatidilinositol 3-Quinasas/fisiología , FosforilaciónRESUMEN
SH2 domains are discrete structural motifs common to a variety of critical intracellular signaling proteins. Inhibitors of specific SH2 domains have become important therapeutic targets in the treatment and/or prevention of restenosis, cancers (including small cell lung), cardiovascular disease, osteoporosis, apoptosis among others. Considering the social and economic impact of these diseases significant attention has been focused on the development of potent and selective inhibitors of specific SH2 domains. In particular, considerable research has been performed on Src, PI 3-kinase, Grb2 and more recently, Lck. In this review, we will focus on progress in the development of inhibitors for these specific SH2 domains and evaluate potential future targets.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Dominios Homologos src/efectos de los fármacos , Secuencia de Aminoácidos , Animales , Diseño de Fármacos , Inhibidores Enzimáticos/química , Humanos , Modelos Moleculares , Datos de Secuencia Molecular , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/química , Familia-src Quinasas/antagonistas & inhibidores , Familia-src Quinasas/químicaRESUMEN
50 patients with a degenerative shoulder-syndrome with impingement are evaluated by questioning and 17 clinical tests. Also taking in account findings of plain x-rays they are classified preoperatively as "rotator cuff tear" or "no tear". Only 4 of the maneuvers are positive in more than 66% of cases. Jobe test and Eppendorf test are especially useful in diagnosing an impingement syndrome. A painful are is found in only 48.9%. In the rupture group 9.7 maneuvers are positive while in the non rupture group it is 7.7 in the mean (not significant). Because no significant differences are noticed between groups for any of the tests a cuff tear can not be ruled out by a single sign. The overall rate of positive tests of both authors is similar (41.1%, 45.8%) but in detail differences are found in 21.2%. Useful (significant, p < 0.05) data for diagnosing a tear are older age (56.1 years vs. 47.7 years. in the non rupture group), previous (minor) trauma and radiological findings on plain films suggesting periarticular degenerative lesions. A calcifying tendinitis is consistent with pure impingement. The correct diagnosis confirmed by operation is made in 90% (sensitivity 91.3%, specificity 88.9%). This can be achieved only by an experienced clinician who takes into account all anamnestic and clinical findings, especially details that cannot be classified as just positive or negative and thus cannot be computerized.